Harbor Capital Advisors Inc. Has $413,000 Position in Avanos Medical, Inc. (NYSE:AVNS)

Harbor Capital Advisors Inc. boosted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 14,386.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 28,829 shares of the company’s stock after purchasing an additional 28,630 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.06% of Avanos Medical worth $413,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Avanos Medical in the 4th quarter valued at about $64,000. State of Wyoming raised its position in shares of Avanos Medical by 132.0% during the fourth quarter. State of Wyoming now owns 5,137 shares of the company’s stock worth $82,000 after purchasing an additional 2,923 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Avanos Medical by 493.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock worth $129,000 after purchasing an additional 6,714 shares during the period. EP Wealth Advisors LLC lifted its holdings in shares of Avanos Medical by 14.6% in the 4th quarter. EP Wealth Advisors LLC now owns 10,108 shares of the company’s stock worth $161,000 after purchasing an additional 1,289 shares in the last quarter. Finally, Heritage Family Offices LLP acquired a new stake in Avanos Medical in the 1st quarter valued at $146,000. 95.17% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Avanos Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th.

Avanos Medical Stock Down 2.1%

Shares of NYSE:AVNS opened at $12.11 on Friday. The business’s 50 day moving average is $12.52 and its 200 day moving average is $14.79. Avanos Medical, Inc. has a 12-month low of $11.84 and a 12-month high of $25.36. The stock has a market cap of $560.01 million, a price-to-earnings ratio of 35.62 and a beta of 1.14. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.07. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The firm had revenue of $167.50 million during the quarter, compared to analyst estimates of $161.75 million. During the same quarter in the prior year, the business posted $0.22 EPS. The business’s revenue was up .8% compared to the same quarter last year. On average, sell-side analysts forecast that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.